๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

RecruitingNAAges 18 Years - 90 YearsAllNurettin ลžahin
NCT07482566 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with locally advanced Siewert type II-III gastroesophageal junction cancer. Eligible patients will be randomly assigned to undergo either proximal gastrectomy or total gastrectomy using open, laparoscopic, or robotic surgical approaches according to clinical suitability. The primary outcome of the study is 3-year disease-free survival. Secondary outcomes include postoperative mortality, postoperative complications, and the number of metastatic lymph nodes retrieved. Patients will be followed for up to five years after surgery to evaluate long-term oncological outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age between 18 and 90 years * Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer * Considered operable after multidisciplinary tumor board evaluation * Candidate for curative surgical resection with D2 lymphadenectomy * Provision of written informed consent Exclusion Criteria: * Early-stage gastroesophageal junction cancer * Gastric cancers located in the antrum or corpus * Severe anesthetic risk (American Society of Anesthesiologists \[ASA\] class IV or higher) * Pregnancy * Patients unwilling or unable to provide informed consent
๐Ÿ’Š

What it tests

  • Proximal Gastrectomy
  • Total Gastrectomy
๐Ÿ“

Where

1 site
Bakirkoy Dr. Sadi Konuk Training and Research Hospital
Istanbul, Turkey (Tรผrkiye)
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy